4SC AG (VSC.DU): Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model  
5/27/2011 11:05:16 AM

4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus (SLE) at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.